Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 10 tags : Therapy save search
Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting
Published: 2021-06-10 (Crawled : 23:00) - prnewswire.com
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.18%
H: 0.52%
C: -0.91%
therapy
More Release. Less Squeeze. SmartVest Airway Clearance Therapy
Published: 2021-06-10 (Crawled : 22:00) - electromed.com
ELMD | $16.39 4.26% 0.0% 66K
|
Health Technology
|
| O: 0.18%
H: 0.81%
C: -2.6%
therapy clearance
Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
Published: 2021-06-10 (Crawled : 22:00) - prnewswire.com
PGEN | $1.4 1.45% 1.43% 510K
|
Health Technology
|
| O: 23.32%
H: 1.16%
C: -14.97%
diabetes phase 1 positive therapy results topline iot phase 1b designation phase 2b
Akoya Announces Publication of New Immunotherapy Biomarker Signature in Science, Leveraging Principles of Astronomy and Pathology
Published: 2021-06-10 (Crawled : 19:00) - globenewswire.com
AKYA | News | $3.82 -2.05% -2.09% 86K
|
Professional, Scientific, and T...
|
| O: -0.25%
H: 2.03%
C: 0.96%
immunotherapy therapy biomarkers
ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients
Published: 2021-06-10 (Crawled : 13:15) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 0.2%
H: 2.21%
C: -3.24%
phase 2 phase 1 therapy hiv phase 3 injection infections
Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program
Published: 2021-06-10 (Crawled : 13:00) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 3.84%
H: 8.15%
C: -1.74%
covid positive therapy antiviral preclinical covid-19 pre-clinical
Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC
Published: 2021-06-10 (Crawled : 12:15) - globenewswire.com
CUE | $1.51 -3.82% -3.97% 160K
|
Health Technology
|
| O: 0.84%
H: 3.62%
C: 2.59%
biopharma phase 1 expansion therapy trial phase 3 phase 2
Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder
Published: 2021-06-10 (Crawled : 12:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.35%
H: 1.75%
C: 1.34%
CDXS | $2.895 1.22% 1.21% 190K
|
Process Industries
|
| O: -0.05%
H: 4.39%
C: 3.16%
genetic gene therapy therapy collaboration license gene therapies rare
Bio-Techne Further Enhances Its Gene Engineering & Cell & Gene Therapy Manufacturing Capabilities
Published: 2021-06-10 (Crawled : 12:00) - biospace.com/
TECH | $63.675 1.39% 1.37% 1.2M
|
Health Technology
|
| O: 0.21%
H: 2.55%
C: 1.34%
gene therapy therapy gene therapies
Taysha Gene Therapies to Host First Annual Stockholder Meeting
Published: 2021-06-10 (Crawled : 12:00) - biospace.com/
TSHA | $2.525 2.64% 2.57% 1.5M
|
Health Technology
|
| O: 0.62%
H: 4.35%
C: 1.82%
gene therapies therapy gene therapy
New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy
Published: 2021-06-10 (Crawled : 12:00) - globenewswire.com
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: -0.14%
H: 4.04%
C: 3.63%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.0%
H: 4.89%
C: 1.91%
therapy
Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer
Published: 2021-06-10 (Crawled : 11:00) - biospace.com/
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.02%
H: 2.4%
C: 2.12%
disease sensor gene therapy therapy gene therapies rare
MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases
Published: 2021-06-10 (Crawled : 11:00) - globenewswire.com
MNKD | $4.15 0.97% 0.96% 1M
|
Health Technology
|
| O: 0.98%
H: 0.73%
C: -2.18%
disease potential therapy
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.